Your browser doesn't support javascript.
loading
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Meininger, Vincent; Genge, Angela; van den Berg, Leonard H; Robberecht, Wim; Ludolph, Albert; Chio, Adriano; Kim, Seung H; Leigh, P Nigel; Kiernan, Matthew C; Shefner, Jeremy M; Desnuelle, Claude; Morrison, Karen E; Petri, Susanne; Boswell, Diane; Temple, Jane; Mohindra, Rajat; Davies, Matt; Bullman, Jonathan; Rees, Paul; Lavrov, Arseniy.
Afiliação
  • Meininger V; Ramsay Generale de Sante Hopital Prive Peupliers, Paris, France.
  • Genge A; Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada.
  • van den Berg LH; Department of Neurology, Brain Centre Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands.
  • Robberecht W; KU Leuven, Department of Neurosciences, Experimental Neurology University Hospitals Leuven, Department of Neurology, Leuven, Belgium.
  • Ludolph A; Department of Neurology, University of Ulm, Ulm, Germany.
  • Chio A; Rita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy.
  • Kim SH; Department of Neurology, Hanyang University Medical Center, Seoul, South Korea.
  • Leigh PN; Division of Medicine (Neurology), Trafford Centre for Biomedical Research, Brighton and Sussex Medical School, University of Sussex, East Sussex, UK.
  • Kiernan MC; Brain & Mind Centre, Sydney Medical School, the University of Sydney, Sydney, NSW, Australia.
  • Shefner JM; Barrow Neurological Institute, Phoenix, AZ, USA.
  • Desnuelle C; Department of Neurology, University Hospital of Nice, Nice, France.
  • Morrison KE; Institute of Clinical Sciences, University of Birmingham, Edgbaston, Birmingham, UK; Faculty of Medicine, University of Southampton, University Hospital Southampton, Southampton, UK.
  • Petri S; Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Boswell D; Neurosciences Therapy Area Unit, GlaxoSmithKline, Uxbridge, UK.
  • Temple J; R&D Projects Clinical Platforms and Sciences, Quantitative Sciences, Clinical Statistics, GlaxoSmithKline, Uxbridge, UK.
  • Mohindra R; Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Uxbridge, UK.
  • Davies M; Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Uxbridge, UK.
  • Bullman J; Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Stevenage, UK.
  • Rees P; Neurosciences Therapy Area Unit, GlaxoSmithKline, Uxbridge, UK.
  • Lavrov A; Neurosciences Therapy Area Unit, GlaxoSmithKline, Uxbridge, UK. Electronic address: arseniy.j.lavrov@gsk.com.
Lancet Neurol ; 16(3): 208-216, 2017 03.
Article em En | MEDLINE | ID: mdl-28139349
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resultado do Tratamento / Anticorpos Monoclonais Humanizados / Proteínas Nogo / Esclerose Lateral Amiotrófica / Fatores Imunológicos Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resultado do Tratamento / Anticorpos Monoclonais Humanizados / Proteínas Nogo / Esclerose Lateral Amiotrófica / Fatores Imunológicos Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article